中性粒细胞性皮肤病（ND）通常继发于炎症、药物暴露和血液恶性肿瘤。虽然血液癌患者中恶性肿瘤相关 ND (MA-ND) 的报道较多，但对该人群中药物诱导的 ND (DI-ND) 知之甚少。本研究的目的是比较发生 MA-ND 和 DI-ND 的血液恶性肿瘤患者的表现和结果。从我们机构的电子病历中识别出 2013 年至 2023 年之间发生的血液恶性肿瘤患者中的 ND 病例。回顾了患者特征、近期药物暴露、癌症突变和疾病结果。如果患者最近接触过已知通常与 ND 相关的四种药物之一，则患者被归类为 DI-ND，或者被归类为 MA-ND。我们报告了 DI-ND 和 MA-ND 病例的描述性分析。我们确定了 52 例 ND 和并发血液恶性肿瘤患者，其中 16 例 DI-ND (30.8%) 和 36 例 MA-ND (69.2%) 。两组中最常见的 ND 是斯威特综合征。包括实体瘤、炎症性疾病、慢性病毒感染和吸烟在内的慢性基础疾病在 MA-ND 患者中更为常见。在 DI-ND 患者中，酪氨酸激酶抑制剂是最常见的相关药物（43.8%）。 DI-ND 患者中最常见的癌症突变是 FLT3 (43.8%)，而 MA-ND 患者中最常见的癌症突变是 TP-53 (19.4%)。在数据收集时已死亡的患者中，90.0% 的 DI-ND 患者和 66.7% 的 MA-ND 患者在 ND 诊断后 1 年内死亡。大多数伴随血液系统恶性肿瘤发生的 ND 病例继发于癌症，而不是继发于癌症。比药物暴露。不同的癌症突变可能导致 DI-ND 和 MA-ND。需要进一步研究来建立 DI-ND 的诊断标准，并确定特定癌症突变（尤其是 FLT3）在 ND 发展中的致病作用。© 2024 S. Karger AG，巴塞尔。

Neutrophilic dermatoses (NDs) often occur secondary to inflammatory conditions, medication exposure, and hematologic malignancy. While malignancy-associated NDs (MA-NDs) have been well reported among those with hematologic cancers, little is known about drug-induced NDs (DI-NDs) within this population. The objective of this study was to compare the presentations and outcomes of patients with hematologic malignancies who developed MA-NDs and DI-NDs.Cases of ND occurring between 2013 and 2023 among those with hematologic malignancies were identified from the electronic medical records of our institution. Patient characteristics, recent medication exposures, cancer mutations, and disease outcomes were reviewed. Patients were categorized with DI-ND if they were recently exposed to one of four medications known to be commonly associated with ND or were otherwise categorized with MA-ND. We report a descriptive analysis of cases of DI-ND and MA-ND.We identified 52 patients with ND and co-occurring hematologic malignancy including 16 cases of DI-ND (30.8%) and 36 cases of MA-ND (69.2%). The most common ND in both groups was Sweet's syndrome. Chronic underlying conditions including solid tumors, inflammatory disorders, chronic viral infection, and tobacco use were more common among those with MA-ND. Among those with DI-ND, tyrosine kinase inhibitors were the most commonly associated drugs (43.8%). The most common cancer mutation among those with DI-ND was FLT3 (43.8%), while the most common mutation among those with MA-ND was TP-53 (19.4%). Among those who had died at the time of data collection, 90.0% of those with DI-ND and 66.7% of those with MA-ND died within 1 year of ND diagnosis.Most cases of ND occurring with hematologic malignancies develop secondary to cancer rather than drug exposure. Different cancer mutations may predispose to DI-ND and MA-ND. Further research is needed to establish diagnostic criteria for DI-ND and to determine the pathogenic role of specific cancer mutations, particularly FLT3, in the development of ND.© 2024 S. Karger AG, Basel.